Name: Metronidazole
Brand: Selleck Chemicals
SKU: S1907
Availability: InStock
Rating: 5 (4 reviews)

Jump to

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase
Other Antineoplastic and Immunosuppressive Antibiotics Inhibitors	Staurosporine (STS) Cyclosporin A Oligomycin A (MCH 32) Puromycin Dihydrochloride Nigericin sodium salt Geldanamycin (NSC 122750) Honokiol Streptozotocin (STZ) Sodium Monensin (NSC 343257) Hygromycin B

Solubility

In vitro
Batch:

DMSO : 34 mg/mL (198.65 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 12 mg/mL (Warmed with 50℃ water bath; Ultrasonicated)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.7mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 34 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.24mg/ml (1.40mM)	Taking the 1 mL working solution as an example, add 50 μL of 4.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	171.15	Formula	C₆H₉N₃O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	443-48-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC1=NC=C(N1CCO)[N+](=O)[O-]

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	DNA synthesis
In vitro	Metronidazole is relatively inactive until it is metabolized within host or microbial cells. It is activated when it receives an electron from ferredoxin or flavodoxin that is reduced by POR in anaerobic or microaerophilic bacteria or luminal parasites. This compound damages cells by forming protein and DNA adducts. It has activity against protozoans like Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis, for which the drug is first approved as an effective treatment. The activity of this chemical against anaerobic bowel flora has been used for prophylaxis and treatment of patients with Crohn's disease who might develop an infectious complication. It has played an important role in anaerobic-related infections. This compound has notable effectiveness in treating anaerobic brain abscesses. Its resistance tends to result from de novo mutation in the resident rdxA gene, rather than from lateral transfer of mutant rdxA (or other) genes from unrelated but Mtzr strains. It partially inhibits growth stimulate forward mutation to rifampin resistance in rdxA(+) (Metronidazole(s)) and also in rdxA (Metronidazole(r)) H. pylori strains, and that expression of rdxA in Escherichia coli results in equivalent Mtz-induced mutation. This compound leads to apoptosis-like features in growing cultures of axenic B. hominis, including key morphological and biochemical features of programmed cell death (PCD), viz. nuclear condensation and nicked DNA in nucleus, reduced cytoplasmic volume, externalization of phosphatidylserine and maintenance of plasma membrane integrity with increasing permeability.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10390199/ [2] https://pubmed.ncbi.nlm.nih.gov/1720382/ [3] https://pubmed.ncbi.nlm.nih.gov/10960092/ [4] http://www.ncbi.nlm.nih.gov/pubmed/ 14702395

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-11-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06509139	ENROLLING_BY_INVITATION	Helicobacter Pylori Infection; Sex; Bismuth Quadruple Therapy	National Cheng-Kung University Hospital	2024-07-09	PHASE4
NCT06616597	RECRUITING	Prostate Cancer (Adenocarcinoma); Metastatic Prostate Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2025-02-13	PHASE2
NCT04415983	RECRUITING	Helicobacter Pylori Infection	Tanta University	2020-06-01	PHASE3
NCT07144657	NOT_YET_RECRUITING	MALT Lymphoma of Stomach	National Taiwan University Hospital	2025-09-01	PHASE2
NCT06349122	NOT_YET_RECRUITING	Bacterial Vaginosis; Vaginal Dysbiosis; Premature Delivery	Assistance Publique Hopitaux De Marseille	2026-10	PHASE3
NCT06261840	RECRUITING	Trichomonas Vaginitis; Bacterial Vaginitis	Tulane University	2025-05-06	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Metronidazole Antineoplastic and Immunosuppressive Antibiotics inhibitor

Chemical Structure

Molecular Weight: 171.15